Juniper UK

Juniper is a women's health-focused digital weight management programme operating in the UK and Australia. The UK platform offers injectable weight loss treatment (semaglutide and tirzepatide, marketed under MHRA-compliant descriptions) alongside a coaching programme centred on nutrition and strength training. Juniper reduced the price of its semaglutide injectable programme by 25% following Eli Lilly's September 2025 Mounjaro price increase, making it one of the more competitively priced full-service providers in the market. The platform also offers a seven-day switching protocol for patients moving between injectable treatments — faster than the 28-day period most providers require. Clinically, Juniper is registered with the General Pharmaceutical Council (GPhC: 9011842) and regulated by the Care Quality Commission (CQC). Monthly costs typically range from £99 to £289 depending on the medication and dose. The coaching programme includes dietitian-reviewed nutrition plans and exercise guidance focused on strength training and muscle preservation during weight loss.